You can hardly blame Eugene Melnyk for being disappointed with his investment in Acerus Pharmaceuticals. The value of his shares in the Toronto company he founded have plummeted 97 per cent since May 2012 to just $3 million. As to whether there is merit in his recently launched $145 million suit against the company, executives […]